DK3079719T3 - ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf - Google Patents

ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number: DK3079719T3
Authority: DK; Denmark
Prior art keywords: siglec; antibodies; methods
Prior art date: 2013-12-09

Application number

DK14869424T

Other languages

English (en)

Inventor

Christopher R Bebbington

Rustom Falahati

Fernandes Carolina Rita Sousa

David John Matthews

Nenad Tomasevic

Jason Williams

John Leung

Original Assignee

Allakos Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-09

Filing date

2014-12-09

Publication date

2019-11-18

2014-12-09 Application filed by Allakos Inc filed Critical Allakos Inc

2019-11-18 Application granted granted Critical

2019-11-18 Publication of DK3079719T3 publication Critical patent/DK3079719T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK14869424T 2013-12-09 2014-12-09 ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf DK3079719T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361913891P	2013-12-09	2013-12-09
PCT/US2014/069409 WO2015089117A1 (en)	2013-12-09	2014-12-09	Anti-siglec-8 antibodies and methods of use thereof

Publications (1)

Publication Number	Publication Date
DK3079719T3 true DK3079719T3 (da)	2019-11-18

Family

ID=53371783

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14869424T DK3079719T3 (da)	2013-12-09	2014-12-09	ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf

Country Status (24)

Country	Link
US (4)	US9546215B2 (da)
EP (2)	EP3611191A1 (da)
JP (4)	JP6549143B2 (da)
KR (3)	KR20210125114A (da)
CN (3)	CN113861293A (da)
AU (2)	AU2014363944B2 (da)
BR (1)	BR112016013109B1 (da)
CA (1)	CA2930886C (da)
CY (1)	CY1122329T1 (da)
DK (1)	DK3079719T3 (da)
ES (1)	ES2758508T3 (da)
HR (1)	HRP20192052T1 (da)
HU (1)	HUE047283T2 (da)
IL (3)	IL298470A (da)
LT (1)	LT3079719T (da)
NZ (1)	NZ720769A (da)
PL (1)	PL3079719T3 (da)
PT (1)	PT3079719T (da)
RS (1)	RS59567B1 (da)
SG (2)	SG11201604632PA (da)
SI (1)	SI3079719T1 (da)
SM (1)	SMT201900714T1 (da)
WO (1)	WO2015089117A1 (da)
ZA (1)	ZA201603435B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3110446T3 (da) *	2014-02-28	2022-02-28	Allakos Inc	Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US10774145B2 (en) *	2015-06-17	2020-09-15	Allakos Inc.	Methods and compositions for treating fibrotic diseases
US10604577B2 (en) *	2015-10-22	2020-03-31	Allakos Inc.	Methods and compositions for treating systemic mastocytosis
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US20190338027A1 (en) *	2017-01-06	2019-11-07	Allakos Inc.	Methods and compositions for treating chronic obstructive pulmonary disorder
EP3618868A4 (en) *	2017-05-05	2021-02-24	Allakos Inc.	METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
EP3618872A4 (en) *	2017-05-05	2021-06-30	Allakos Inc.	METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY STOMACH AND INTESTINAL DISEASES
WO2019133818A1 (en)	2017-12-29	2019-07-04	Cornell University	Gene therapy for eosinohilic disorders
CN112384535A (zh) *	2018-05-04	2021-02-19	爱乐科斯公司	用于治疗慢性荨麻疹的方法和组合物
CA3130072A1 (en) *	2019-02-15	2020-08-20	Bradford Andrew Youngblood	Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
JP2022542472A (ja) *	2019-08-02	2022-10-03	アラコスインコーポレイテッド	抗ｓｉｇｌｅｃ－８抗体および副腎皮質ステロイド薬を投与する方法
EP4048698A4 (en) *	2019-10-24	2023-12-06	Allakos Inc.	Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
CN114945592B (zh) *	2019-11-19	2025-09-19	宾夕法尼亚大学董事会	抗-α-突触核蛋白单克隆抗体及其使用方法
WO2021247821A1 (en) *	2020-06-03	2021-12-09	The Wistar Institute Of Anatomy And Biology	Monoclonal antibodies against human siglec-9 and use thereof for immunotherapy
WO2022061032A1 (en) *	2020-09-17	2022-03-24	Allakos Inc.	Methods and compositions for treating viral infection
WO2022215566A1 (ja) *	2021-04-05	2022-10-13	国立大学法人筑波大学	アレルギー性疾患の予防又は治療剤
WO2023215907A1 (en) *	2022-05-06	2023-11-09	Seattle Children's Hospital D/B/A Seattle Children's Research Institute	Inhibiting mast cell activation by binding sialic acid-binding immunoglobulin-like lectin-9 (siglec-9)
WO2024043940A1 (en) *	2022-08-25	2024-02-29	Allakos Inc.	Methods and compositions for treating atopic dermatitis
WO2024254441A1 (en) *	2023-06-08	2024-12-12	Allakos Inc.	Bispecific antibodies to siglec-6 and siglec-8 and methods of use thereof

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE30985E (en)	1978-01-01	1982-06-29		Serum-free cell culture media
US4419446A (en)	1980-12-31	1983-12-06	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en)	1982-11-24	1986-07-22	The Regents Of The University Of California	Mammalian metallothionein promoter system
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4965199A (en)	1984-04-20	1990-10-23	Genentech, Inc.	Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en)	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
EP0435911B1 (en)	1988-09-23	1996-03-13	Cetus Oncology Corporation	Cell culture medium for enhanced cell growth, culture longevity and product expression
ES2052027T5 (es)	1988-11-11	2005-04-16	Medical Research Council	Clonacion de secuencias de dominio variable de inmunoglobulina.
US5891693A (en)	1990-01-25	1999-04-06	Alusuisse Holdings A.G.	Recombinant DNA methods vectors and host cells
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5508192A (en)	1990-11-09	1996-04-16	Board Of Regents, The University Of Texas System	Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en)	1990-11-09	1993-11-23	Board Of Regents, The University Of Texas System	Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
DE69233254T2 (de)	1991-06-14	2004-09-16	Genentech, Inc., South San Francisco	Humanisierter Heregulin Antikörper
JP3951062B2 (ja)	1991-09-19	2007-08-01	ジェネンテック・インコーポレーテッド	少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
CA2119930C (en)	1991-09-23	2002-10-01	Hendricus R. J. M. Hoogenboom	Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
DE69334351D1 (de)	1992-02-06	2011-05-12	Novartis Vaccines & Diagnostic	Biosynthetisches Bindeprotein für Tumormarker
EP0640094A1 (en)	1992-04-24	1995-03-01	The Board Of Regents, The University Of Texas System	Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0752248B1 (en)	1992-11-13	2000-09-27	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5885573A (en)	1993-06-01	1999-03-23	Arch Development Corporation	Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en)	1993-06-16	1998-05-28	Celltech Therapeutics Limited	Antibodies
US5639635A (en)	1994-11-03	1997-06-17	Genentech, Inc.	Process for bacterial production of polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en)	1995-04-14	2000-09-19	Genentech, Inc.	Altered polypeptides with increased half-life
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
AU2660397A (en)	1996-04-05	1997-10-29	Board Of Regents, The University Of Texas System	Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6277375B1 (en)	1997-03-03	2001-08-21	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
US6083715A (en)	1997-06-09	2000-07-04	Board Of Regents, The University Of Texas System	Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
JP2002506353A (ja)	1997-06-24	2002-02-26	ジェネンテック・インコーポレーテッド	ガラクトシル化糖タンパク質の方法及び組成物
AU759779B2 (en)	1997-10-31	2003-05-01	Genentech Inc.	Methods and compositions comprising glycoprotein glycoforms
ATE531812T1 (de)	1997-12-05	2011-11-15	Scripps Research Inst	Humanisierung von nager-antikörpern
DK1068241T3 (da)	1998-04-02	2008-02-04	Genentech Inc	Antistofvarianter og fragmenter deraf
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
DK2180007T4 (da)	1998-04-20	2017-11-27	Roche Glycart Ag	Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
MX353234B (es)	1999-01-15	2018-01-08	Genentech Inc	Variantes de polipeptidos con función efectora alterada.
DK1176195T3 (da)	1999-04-09	2013-06-24	Kyowa Hakko Kirin Co Ltd	Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
WO2001029246A1 (fr)	1999-10-19	2001-04-26	Kyowa Hakko Kogyo Co., Ltd.	Procede de production d'un polypeptide
JP4860877B2 (ja) *	2000-03-07	2012-01-25	ジョンズ・ホプキンス・ユニバーシティ	シアロアドへジンファクター−２抗体
US20030092091A1 (en) *	2000-03-07	2003-05-15	Abrahamson Julie A.	Sialoadhesin factor-2 antibodies
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
DE60143544D1 (de)	2000-12-12	2011-01-05	Medimmune Llc	Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
WO2003011878A2 (en)	2001-08-03	2003-02-13	Glycart Biotechnology Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (en)	2001-10-25	2012-12-04	Genentech, Inc.	Glycoprotein compositions
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
CA2481925A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Therapeutic agent for patients having human fc.gamma.riiia
AU2003236017B2 (en)	2002-04-09	2009-03-26	Kyowa Kirin Co., Ltd.	Drug containing antibody composition
BR0309145A (pt)	2002-04-09	2005-02-01	Kyowa Hakko Kogyo Kk	Células das quais o genoma é modificado
JPWO2003085119A1 (ja)	2002-04-09	2005-08-11	協和醗酵工業株式会社	抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法
DE60336548D1 (de)	2002-04-09	2011-05-12	Kyowa Hakko Kirin Co Ltd	Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
WO2003085118A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Process for producing antibody composition
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
RS20100366A (sr)	2002-12-16	2011-04-30	Genentech, Inc.	Varijante imunoglobulina i njihova upotreba
EP1688439A4 (en)	2003-10-08	2007-12-19	Kyowa Hakko Kogyo Kk	COMPOSITION OF CONDENSED PROTEINS
AU2004280065A1 (en)	2003-10-09	2005-04-21	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
HUE042914T2 (hu)	2003-11-05	2019-07-29	Roche Glycart Ag	CD20 antitestek fokozott fc receptorkötõ affinitással és effektorfunkcióval
JPWO2005053742A1 (ja)	2003-12-04	2007-06-28	協和醗酵工業株式会社	抗体組成物を含有する医薬
US7981843B2 (en)	2004-01-20	2011-07-19	Kalobios Pharmaceuticals, Inc.	Antibody specificity transfer using minimal essential binding determinants
WO2005116088A2 (en)	2004-05-25	2005-12-08	The Johns Hopkins University	Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2006055778A2 (en)	2004-11-16	2006-05-26	Kalobios, Inc.	Immunoglobulin variable region cassette exchange
US8357671B2 (en)	2005-11-10	2013-01-22	James Paulson	High affinity Siglec ligands
US20070134259A1 (en)	2005-11-21	2007-06-14	David Bundle	Methods and compositions for pharmacologially controlled targeted immunotherapy
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
PL2282773T3 (pl)	2008-05-02	2014-08-29	Seattle Genetics Inc	Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
ES2531561T3 (es) *	2009-08-28	2015-03-17	Regeneron Pharmaceuticals, Inc.	Anticuerpos de antiquina que se enlazan a múltiples quimioquinas CC
MX2012003404A (es)	2009-09-22	2012-09-12	Volker Sandig	Procedimiento para producir moleculas que contienen estructuras de glicano especializadas.
US8586044B2 (en)	2010-05-28	2013-11-19	Northwestern University	Treatment of chronic pelvic pain syndrome
EP2465873A1 (en)	2010-12-16	2012-06-20	Deutsches Rheuma-Forschungszentrum Berlin	Eosinophils as a therapeutic target
CN109797138A (zh) *	2011-03-06	2019-05-24	默克雪兰诺有限公司	低岩藻糖细胞系及其应用
US9434786B2 (en) *	2012-02-10	2016-09-06	University Of Maryland, Baltimore	Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
DK3110446T3 (da) *	2014-02-28	2022-02-28	Allakos Inc	Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
US10604577B2 (en) *	2015-10-22	2020-03-31	Allakos Inc.	Methods and compositions for treating systemic mastocytosis
EP3618868A4 (en) *	2017-05-05	2021-02-24	Allakos Inc.	METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES

2014
- 2014-12-09 AU AU2014363944A patent/AU2014363944B2/en active Active
- 2014-12-09 DK DK14869424T patent/DK3079719T3/da active
- 2014-12-09 KR KR1020217032002A patent/KR20210125114A/ko not_active Ceased
- 2014-12-09 JP JP2016557547A patent/JP6549143B2/ja active Active
- 2014-12-09 HR HRP20192052TT patent/HRP20192052T1/hr unknown
- 2014-12-09 PL PL14869424T patent/PL3079719T3/pl unknown
- 2014-12-09 WO PCT/US2014/069409 patent/WO2015089117A1/en not_active Ceased
- 2014-12-09 NZ NZ720769A patent/NZ720769A/en unknown
- 2014-12-09 US US14/565,370 patent/US9546215B2/en active Active
- 2014-12-09 CN CN202111165428.8A patent/CN113861293A/zh active Pending
- 2014-12-09 BR BR112016013109-6A patent/BR112016013109B1/pt active IP Right Grant
- 2014-12-09 PT PT148694243T patent/PT3079719T/pt unknown
- 2014-12-09 KR KR1020167018130A patent/KR102311761B1/ko active Active
- 2014-12-09 SG SG11201604632PA patent/SG11201604632PA/en unknown
- 2014-12-09 RS RS20191504A patent/RS59567B1/sr unknown
- 2014-12-09 ES ES14869424T patent/ES2758508T3/es active Active
- 2014-12-09 CA CA2930886A patent/CA2930886C/en active Active
- 2014-12-09 SG SG10201808835QA patent/SG10201808835QA/en unknown
- 2014-12-09 LT LT14869424T patent/LT3079719T/lt unknown
- 2014-12-09 KR KR1020237021876A patent/KR20230107382A/ko not_active Ceased
- 2014-12-09 EP EP19186014.7A patent/EP3611191A1/en not_active Withdrawn
- 2014-12-09 CN CN202111165415.0A patent/CN114044825A/zh active Pending
- 2014-12-09 CN CN201480067583.8A patent/CN105916519B/zh active Active
- 2014-12-09 SI SI201431406T patent/SI3079719T1/sl unknown
- 2014-12-09 EP EP14869424.3A patent/EP3079719B8/en active Active
- 2014-12-09 SM SM20190714T patent/SMT201900714T1/it unknown
- 2014-12-09 HU HUE14869424A patent/HUE047283T2/hu unknown
- 2014-12-09 IL IL298470A patent/IL298470A/en unknown
2016
- 2016-05-16 IL IL245663A patent/IL245663B/en active IP Right Grant
- 2016-05-19 ZA ZA2016/03435A patent/ZA201603435B/en unknown
- 2016-12-07 US US15/372,268 patent/US20170209556A1/en not_active Abandoned
2019
- 2019-02-15 JP JP2019025337A patent/JP6963577B2/ja active Active
- 2019-05-17 US US16/416,085 patent/US20200054723A1/en not_active Abandoned
- 2019-11-27 CY CY20191101242T patent/CY1122329T1/el unknown
2020
- 2020-02-25 JP JP2020029472A patent/JP2020078336A/ja not_active Withdrawn
- 2020-06-16 AU AU2020204016A patent/AU2020204016A1/en not_active Abandoned
2021
- 2021-01-13 IL IL280155A patent/IL280155A/en unknown
2022
- 2022-01-26 US US17/585,323 patent/US20220331412A1/en not_active Abandoned
- 2022-04-06 JP JP2022063368A patent/JP2022082715A/ja active Pending

Also Published As

Publication number	Publication date
BR112016013109B1 (pt)	2021-05-11
EP3079719A4 (en)	2017-08-02
CA2930886C (en)	2024-05-21
CN113861293A (zh)	2021-12-31
SG11201604632PA (en)	2016-07-28
US20150203578A1 (en)	2015-07-23
US20200054723A1 (en)	2020-02-20
US20170209556A1 (en)	2017-07-27
IL245663A0 (en)	2016-06-30
JP2017501744A (ja)	2017-01-19
US20220331412A1 (en)	2022-10-20
HUE047283T2 (hu)	2020-04-28
RS59567B1 (sr)	2019-12-31
CA2930886A1 (en)	2015-06-18
EP3079719A1 (en)	2016-10-19
ES2758508T3 (es)	2020-05-05
EP3079719B1 (en)	2019-09-04
EP3079719B8 (en)	2019-12-04
WO2015089117A1 (en)	2015-06-18
US9546215B2 (en)	2017-01-17
PL3079719T3 (pl)	2020-05-18
JP2022082715A (ja)	2022-06-02
SMT201900714T1 (it)	2020-01-14
KR20160095113A (ko)	2016-08-10
CN105916519B (zh)	2021-10-22
JP2019076115A (ja)	2019-05-23
NZ720769A (en)	2022-10-28
JP2020078336A (ja)	2020-05-28
SG10201808835QA (en)	2018-11-29
HRP20192052T1 (hr)	2020-02-07
AU2014363944B2 (en)	2020-03-26
ZA201603435B (en)	2020-08-26
IL245663B (en)	2021-02-28
KR102311761B1 (ko)	2021-10-13
KR20210125114A (ko)	2021-10-15
JP6963577B2 (ja)	2021-11-10
KR20230107382A (ko)	2023-07-14
IL280155A (en)	2021-03-01
AU2014363944A1 (en)	2016-06-09
EP3611191A1 (en)	2020-02-19
LT3079719T (lt)	2019-12-10
BR112016013109A2 (pt)	2017-09-26
PT3079719T (pt)	2019-12-05
CN105916519A (zh)	2016-08-31
CY1122329T1 (el)	2021-01-27
SI3079719T1 (sl)	2019-12-31
JP6549143B2 (ja)	2019-07-24
CN114044825A (zh)	2022-02-15
AU2020204016A1 (en)	2020-07-02
IL298470A (en)	2023-01-01

Publication	Publication Date	Title
IL290972A (en)	2022-05-01	Anti-vista antibodies and fragments
IL289821B (en)	2022-12-01	Compositions and methods for immunotherapy
DK3079719T3 (da)	2019-11-18	ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK3683235T3 (da)	2024-07-08	Anti-IL-33-antistoffer og anvendelser deraf
DK3227336T3 (da)	2019-09-16	Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
DK3192812T3 (da)	2020-07-13	Anti-CD3-antistoffer og fremgangsmåder til anvendelse
DK3026062T3 (da)	2020-10-12	Anti-pd-1-antistof og anvendelse deraf
DK3086807T3 (da)	2022-09-19	Antistoffer og fremgangsmåder til anvendelse
DK3089994T3 (da)	2022-07-04	Fabs-in-tandem-immunglobulin og anvendelser deraf
DK3280441T3 (da)	2021-11-15	Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3258951T3 (da)	2020-04-06	Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3083680T3 (da)	2020-03-16	Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse
DK3027209T3 (da)	2020-11-02	Anti-Activin A-antistoffer og anvendelser deraf
DK3229838T3 (da)	2020-10-19	Anti-C10orf54-antistoffer og anvendelser deraf
DK3126388T3 (da)	2019-07-29	Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
DK3116911T3 (da)	2019-09-30	Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK2914291T3 (da)	2022-05-16	Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2956175T3 (da)	2017-11-27	Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
PL3406633T3 (pl)	2022-05-23	Przeciwciała wieloswoiste, aktywowalne przeciwciała wieloswoiste i metody ich stosowania
IL245036B (en)	2020-10-29	Pesticidal compositions and related methods
IL285527A (en)	2021-09-30	Compositions and methods for immunotherapy
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
DK3065771T3 (da)	2019-06-11	Fremgangsmåder og sammensætninger til vedvarende immunterapi